# The role of gut microbiota in Hirschsprung’s disease: from pathogenic mechanisms to microbiota-targeted therapies

## TL;DR

This review explores how gut microbiota contribute to Hirschsprung’s disease and how targeting them could lead to new treatments.

## Contribution

The paper systematically reviews the role of gut microbiota in HSCR pathogenesis and potential microbiota-targeted therapies.

## Key findings

- HSCR patients show a distinct gut microbial imbalance affecting the intestinal environment and immune status.
- Microbiota-targeted therapies like FMT and probiotics show potential for treating HSCR.
- Gut dysbiosis disrupts the development and function of the enteric nervous system in HSCR.

## Abstract

Hirschsprung’s disease (HSCR) is a common congenital disorder characterized by abnormal enteric nervous system development. Recent studies have demonstrated that gut microbiota and their metabolites play a significant role in the pathogenesis of HSCR. This review systematically examines the interplay between gut dysbiosis and pathophysiological alterations in HSCR, including disruptions in microbial composition, aberrant metabolite profiles, impaired intestinal barrier function, and dysregulated neuro-immune modulation. Research indicates that HSCR patients exhibit a characteristic gut microbial imbalance, which may influence the development and function of the enteric nervous system by altering the intestinal microenvironment, including metabolic profiles and immune status. Furthermore, this review explores the potential therapeutic value of microbiota-targeted interventions, such as probiotics and fecal microbiota transplantation (FMT), in HSCR treatment, providing a theoretical foundation for novel therapeutic strategies. These findings not only enhance the understanding of HSCR pathogenesis but also offer new perspectives for clinical prevention and treatment.